Laurus Labs Delivers Strong Q1 FY27 With 126% Profit Growth

Revenue: Rs 2,026 crore, up 29% year-on-year.
Net profit: Rs 368 crore, up 126%; EBITDA margin improved to 31.8%.

Reader Takeaway: Strong CDMO execution boosts earnings, while large expansion spending remains the key execution challenge.

What just happened

Laurus Labs reported a strong first quarter of FY27, driven by robust growth in its Contract Development and Manufacturing Organisation (CDMO) business and steady performance in its Affordable Medicines segment.

Revenue increased to Rs 2,026 crore from Rs 1,570 crore a year earlier. EBITDA rose 66% to Rs 644 crore, while EBITDA margin expanded by 700 basis points to 31.8%.

Net profit climbed to Rs 368 crore from Rs 163 crore in the corresponding quarter last year. Earnings per share increased to Rs 6.8 from Rs 3.0.

Why this matters

The quarter demonstrates continued improvement in Laurus Labs' business mix. CDMO contributed 31% of revenue and remained the largest growth driver through commercial project supplies, while the Affordable Medicines business continued to generate 69% of revenue.

The improving contribution from higher-value CDMO operations supported significant margin expansion and stronger profitability.

The backstory

The company continues to diversify beyond its traditional antiretroviral portfolio. Management said the Affordable Medicines business is progressing with its strategy to reduce dependence on ARV products while expanding into higher-value opportunities.

Research and development spending rose sharply to Rs 118 crore, equivalent to 5.8% of revenue, mainly to strengthen advanced biologics capabilities, including gene therapy and antibody-drug conjugates.

What changes now

Laurus Labs plans cumulative capital expenditure of more than Rs 3,000 crore across FY27 and FY28, with about 85% directed towards growth projects.

Key projects include:

• Unit 7 large-scale API facility, with Phase 1 targeted during 2027.
• Commercial Gene Therapy and ADC platform with fill-finish capabilities, expected to be qualified by mid-2027.
• Enzyme fermentation facility targeted to become operational by the end of 2026.

Management expects EBITDA margins to remain above 30% from FY27 onward while expanding integrated manufacturing capabilities across biologics, fermentation and high-potency products.

Risks to watch

Execution of the large capital expenditure programme remains critical. Investors should monitor project commissioning timelines, customer additions in CDMO, utilisation of new facilities and sustained margin performance as investments scale up.

What to track next

Key indicators include CDMO order momentum, commissioning of new manufacturing facilities, progress in advanced biologics infrastructure, R&D intensity and the sustainability of EBITDA margins above the 30% level.